CD4 and renal cell carcinoma: In addition, in patients with stage III RCC, there was no significant difference between sexes (p > 0.05), except for a higher number of CD4 + T cells/living cells in female than in male patients (p = 0.0344) (Supplementary Fig. 5 and Supplementary Table 6).